Ipsen, a global biopharmaceutical company committed to improving patients' lives through breakthrough innovations, focuses on unmet medical needs, particularly in oncology, rare diseases and neuroscience. We support the objectives of the reform but urge more ambition to foster innovation for people with rare diseases and improve Europes competitiveness and attractiveness.
IP
Ipsen Pharma
Company · France · EU Transparency Register 84295189159-07
2
positions filed
in the 583 files tracked
2
legislative files
of 583 tracked
0
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1048 companies & groups on this site, they rank #554 by legislative files engaged — a count of participation, not a measure of influence.
0.2
declared lobbying FTE
self-declared
€100K+
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2012
in the register since
Declares membership of
- Ipsen Pharma is a member of several organisations that may engage in activities covered by the Register:
- EFPIA →
- EuropaBio →
- EUCOPE
Self-declared to the EU Transparency Register (snapshot 2 Sept 2026).
- Register category
- Companies & groups
- Head office
- Paris, France
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 2 Sept 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Ipsen in PolicySpeak: request access →
Work at Ipsen Pharma? so we know who speaks for it.
Their record over time
Ipsen Pharma filed 2 positions between 6 Jan 2021 and 6 Nov 2023, across 2 of the 583 legislative files tracked here.
2021 · 1 filed2023 · 1 filed
What they argued
As a global specialty-driven biopharmaceutical company committed to discovering new solutions for debilitating rare and ultra-rare diseases and improving quality of life for patients suffering from these diseases, Ipsen welcomes the opportunity to comment on the inception impact assessment.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Ipsen Pharma next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
Showing 5 of 52.
Is this your organization?
Everything on this page comes from Ipsen Pharma’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.